Musical chairs as Novartis UK exec becomes Cipla CEO, Glenmark COO moves to Aurobindo
This article was originally published in Scrip
Two large Indian generic companies, Cipla and Aurobindo, have announced top-level appointments, roping in executives with more than two decades of experience each to take charge as their respective chief executive officers (CEOs).
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.